Although treatment-emergent NS3/4A protease inhibitor (PI)-resistant variants typically decrease in frequency after cessation of PI therapy in patients with chronic hepatitis C virus (HCV) infection, HCV susceptibility to PIs in patients who have not responded to previous PI therapy has not been addressed.

Authors: Hiromi Kan, Michio Imamura, Takuro Uchida, Nobuhiko Hiraga, C Nelson Hayes, Masataka Tsuge, Hiromi Abe, Hiroshi Aikata, Grace Naswa Makokha, Sajeda Chowdhury, Daiki Miki, Hidenori Ochi, Yuji Ishida, Chise Tateno, Kazuaki Chayama

Read publication

Back to Resources